Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592876 | 1.00 | LGALS3 (0.33) | LGALS3OGA | |
| SCHEMBL19499295 | 1.00 | LGALS3 (0.33) | LGALS3OGA | |
| SCHEMBL15592892 | 1.00 | LGALS3 (0.33) | LGALS3OGA | |
| SCHEMBL13344830 | 1.00 | LGALS3 (0.33) | LGALS3OGA | |
| SCHEMBL16409826 | 0.83 | SPHK2 (0.31) | — | |
| SCHEMBL24149222 | 0.77 | LGALS3 (0.34) | LGALS3OGA | |
| SCHEMBL903332 | 0.77 | LGALS3 (0.34) | LGALS3OGA | |
| SCHEMBL21312802 | 0.77 | LGALS3 (0.34) | LGALS3OGA | |
| SCHEMBL21312685 | 0.77 | LGALS3 (0.34) | LGALS3OGA | |
| SCHEMBL4077048 | 0.77 | LGALS3 (0.34) | LGALS3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026364-A1 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11840686-B2 | Modulation of prekallikrein (PKK) expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230295629-A1 | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS | UNIVERSITY OF MASSACHUSETTS | 2023-09-21 | — | — | US | disclosed |
| US-11744846-B2 | Allele specific modulators of P23H rhodopsin | IONIS PHARMACEUTICALS INC (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230263822-A1 | MODULATION OF FACTOR 11 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230227824-A1 | COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3 | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20230212564-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230174987-A1 | Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20110172296-A1 | MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION | EXCALIARD PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110160283-A1 | MODULATION OF CD40 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110152351-A1 | MODULATION OF SMRT EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110130441-A1 | OLIGOMERIC COMPOUNDS HAVING AT LEAST ONE NEUTRALLY LINKED TERMINAL BICYCLIC NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110123521-A1 | METHODS FOR MODULATING EXPRESSION OF RBP4 | ISIS PHARMACEUTICALS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110092570-A1 | OLIGOMERIC COMPOUNDS COMPRISING TRICYCLIC NUCELOSIDES AND METHODS FOR THEIR USE | IONIS PHARMACEUTICALS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110077390-A1 | BICYCLIC CYCLOHEXITOL NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100137414-A1 | Modulation of Factor 11 Expression | IONIS PHARMACEUTICALS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100130595-A1 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20090318536-A1 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA | ISS PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744846-B2 | Allele specific modulators of P23H rhodopsin | P2RX3, PDE6A, PDE6C | LGALS3 2785/4885OGA 2757/4885 |
| US-20100137414-A1 | Modulation of Factor 11 Expression | F13B, F13A1, F11 | LGALS3 2584/4885OGA 3638/4885 |
| US-20230263822-A1 | MODULATION OF FACTOR 11 EXPRESSION | F13B, F13A1, F11 | LGALS3 2584/4885OGA 3638/4885 |
| US-20230227824-A1 | COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3 | ATXN2, ATXN2L, ATXN10 | LGALS3 3836/4885OGA 2894/4885 |
| US-20230212564-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION | SERPINA2, SERPINA3, SERPINB1 | LGALS3 981/4885OGA 1751/4885 |
| US-20110152351-A1 | MODULATION OF SMRT EXPRESSION | SREBF1, SREBF2, SRRT | LGALS3 4107/4885OGA 2289/4885 |
| US-20110123521-A1 | METHODS FOR MODULATING EXPRESSION OF RBP4 | RBP4, SREBF2, SREBF1 | LGALS3 587/4885OGA 2155/4885 |
| US-20110092570-A1 | OLIGOMERIC COMPOUNDS COMPRISING TRICYCLIC NUCELOSIDES AND METHODS FOR THEIR USE | NOP2, NSUN2, HNRNPUL1 | LGALS3 1202/4885OGA 425/4885 |
| US-20230174987-A1 | Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression | DMPK, HNRNPK, MYLK2 | LGALS3 3222/4885OGA 2024/4885 |
| US-20110172296-A1 | MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION | TGFB1, SHC1, TGFB2 | LGALS3 866/4885OGA 530/4885 |
| US-20100130595-A1 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF | MMP1, COL14A1, COL2A1 | LGALS3 2258/4885OGA 2483/4885 |
| US-20110160283-A1 | MODULATION OF CD40 EXPRESSION | CD40LG, CD40, SSB | LGALS3 747/4885OGA 979/4885 |
| US-11840686-B2 | Modulation of prekallikrein (PKK) expression | PKLR, GCKR, PKM | LGALS3 3725/4885OGA 1952/4885 |
| US-20240026364-A1 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | TMPRSS6, TFRC, TMPRSS11D | LGALS3 3953/4885OGA 2406/4885 |
| US-20090318536-A1 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA | PCSK9, HMGCR, LDLR | LGALS3 1294/4885OGA 657/4885 |
| US-20110077390-A1 | BICYCLIC CYCLOHEXITOL NUCLEIC ACID ANALOGS | RNGTT, CTDSP1, SUB1 | LGALS3 3314/4885OGA 334/4885 |
| US-20110130441-A1 | OLIGOMERIC COMPOUNDS HAVING AT LEAST ONE NEUTRALLY LINKED TERMINAL BICYCLIC NUCLEOSIDES | NOP2, NSUN2, NSUN3 | LGALS3 2019/4885OGA 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.